Cancer Research Cell Death Mechanisms and Cancer Therapy Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Otte, M.
Right arrow Articles by Pantel, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Otte, M.
Right arrow Articles by Pantel, K.
[Cancer Research 61, 6682-6687, September 15, 2001]
© 2001 American Association for Cancer Research

Advances in Brief

MAGE-A Gene Expression Pattern in Primary Breast Cancer1

Marcus Otte2, Menelaos Zafrakas2, Lutz Riethdorf, Uwe Pichlmeier, Thomas Löning, Fritz Jänicke and Klaus Pantel3

Molekulare Onkologie, Frauenklinik [M. O., M. Z., F. J., K. P.]; Institut für Mathematik und Datenverarbeitung in der Medizin [U. P.]; Abteilung für Gynäkopathologie [L. R., T. L.], Universitätsklinikum Hamburg-Eppendorf, 20251 Hamburg, Germany

Melanoma antigen (MAGE)-A-derived peptides elicit a strong in vitro T-cell response against tumor cells. For determination of MAGE-A1, -2, -3, -4, -6, and -12 expression profile in invasive breast cancer, we developed a multiplex seminested reverse transcription-PCR-method. In total, 18 of 67 (27%) tumors were positive for at least one of these MAGE transcripts, and the expression pattern was heterogeneous: MAGE-A1 was positive in 4 of 67 (6%), MAGE-A2 in 13 of 67 (19%), MAGE-A3 in 7 of 67 (10%), MAGE-A4 in 9 of 67 (13%), MAGE-A6 in 10 of 67 (15%), and MAGE-A12 in 6 of 67 (9%) patients. The MAGE-A transcripts were more frequently expressed in ductal breast carcinomas compared with other histomorphological types. We observed a preferential expression of MAGE-A in patients at a higher risk of recurrence: those harboring tumors with high levels of the protease urokinase-type plasminogen activator and its inhibitor plasminogen activator inhibitor 1, high score of the Ki-67 proliferation antigen, and lesser degree of differentiation. Our findings suggests a potential involvement of MAGE-A in tumor progression, with potential implications for active immunotherapy.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
X. Zhu, S. L. Asa, and S. Ezzat
Fibroblast Growth Factor 2 and Estrogen Control the Balance of Histone 3 Modifications Targeting MAGE-A3 in Pituitary Neoplasia
Clin. Cancer Res., April 1, 2008; 14(7): 1984 - 1996.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Vujanovic, M. Mandic, W. C. Olson, J. M. Kirkwood, and W. J. Storkus
A Mycoplasma Peptide Elicits Heteroclitic CD4+ T Cell Responses against Tumor Antigen MAGE-A6
Clin. Cancer Res., November 15, 2007; 13(22): 6796 - 6806.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Kondo, X. Zhu, S. L. Asa, and S. Ezzat
The Cancer/Testis Antigen Melanoma-Associated Antigen-A3/A6 Is a Novel Target of Fibroblast Growth Factor Receptor 2-IIIb through Histone H3 Modifications in Thyroid Cancer
Clin. Cancer Res., August 15, 2007; 13(16): 4713 - 4720.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Nakagawa, S. R. Martinez, Y. Goto, K. Koyanagi, M. Kitago, T. Shingai, D. A. Elashoff, X. Ye, F. R. Singer, A. E. Giuliano, et al.
Detection of Circulating Tumor Cells in Early-Stage Breast Cancer Metastasis to Axillary Lymph Nodes
Clin. Cancer Res., July 15, 2007; 13(14): 4105 - 4110.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
F. Wischnewski, O. Friese, K. Pantel, and H. Schwarzenbach
Methyl-CpG Binding Domain Proteins and Their Involvement in the Regulation of the MAGE-A1, MAGE-A2, MAGE-A3, and MAGE-A12 Gene Promoters
Mol. Cancer Res., July 1, 2007; 5(7): 749 - 759.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
J. Roman-Gomez, A. Jimenez-Velasco, X. Agirre, J. A. Castillejo, G. Navarro, E. San Jose-Eneriz, L. Garate, L. Cordeu, F. Cervantes, F. Prosper, et al.
Epigenetic regulation of human cancer/testis antigen gene, HAGE, in chronic myeloid leukemia
Haematologica, February 1, 2007; 92(2): 153 - 162.
[Abstract] [Full Text] [PDF]

Home page
 Arch Otolaryngol Head Neck SurgHome page
X. Xie, O. P. F. Clausen, and M. Boysen
Correlation of numerical aberrations of chromosomes x and 11 and poor prognosis in squamous cell carcinomas of the head and neck.
Arch Otolaryngol Head Neck Surg, May 1, 2006; 132(5): 511 - 515.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
F. Wischnewski, K. Pantel, and H. Schwarzenbach
Promoter Demethylation and Histone Acetylation Mediate Gene Expression of MAGE-A1, -A2, -A3, and -A12 in Human Cancer Cells
Mol. Cancer Res., May 1, 2006; 4(5): 339 - 349.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. S. Oh, M. A. Troester, J. Usary, Z. Hu, X. He, C. Fan, J. Wu, L. A. Carey, and C. M. Perou
Estrogen-Regulated Genes Predict Survival in Hormone Receptor-Positive Breast Cancers
J. Clin. Oncol., April 10, 2006; 24(11): 1656 - 1664.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. O. Gure, R. Chua, B. Williamson, M. Gonen, C. A. Ferrera, S. Gnjatic, G. Ritter, A. J.G. Simpson, Y.-T. Chen, L. J. Old, et al.
Cancer-Testis Genes Are Coordinately Expressed and Are Markers of Poor Outcome in Non-Small Cell Lung Cancer
Clin. Cancer Res., November 15, 2005; 11(22): 8055 - 8062.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Z. Duan, Y. Duan, D. E. Lamendola, R. Z. Yusuf, R. Naeem, R. T. Penson, and M. V. Seiden
Overexpression of MAGE/GAGE Genes in Paclitaxel/Doxorubicin-resistant Human Cancer Cell Lines
Clin. Cancer Res., July 1, 2003; 9(7): 2778 - 2785.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Sugita, M. Geraci, B. Gao, R. L. Powell, F. R. Hirsch, G. Johnson, R. Lapadat, E. Gabrielson, R. Bremnes, P. A. Bunn, et al.
Combined Use of Oligonucleotide and Tissue Microarrays Identifies Cancer/Testis Antigens as Biomarkers in Lung Carcinoma
Cancer Res., July 15, 2002; 62(14): 3971 - 3979.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Graff-Dubois, O. Faure, D.-A. Gross, P. Alves, A. Scardino, S. Chouaib, F. A. Lemonnier, and K. Kosmatopoulos
Generation of CTL Recognizing an HLA-A*0201-Restricted Epitope Shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 Tumor Antigens: Implication in a Broad-Spectrum Tumor Immunotherapy
J. Immunol., July 1, 2002; 169(1): 575 - 580.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.